Evidence map›Paper›PMID 36875084›Full record

ArticleFrontiers in immunology2023

LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation.

Juliette Rousse, Pierre-Joseph Royer, Gwénaëlle Evanno, Elsa Lheriteau, Carine Ciron, Apolline Salama, Françoise Shneiker, Roberto Duchi, Andrea Perota, Cesare Galli and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Juliette RousseResearch and Development, Xenothera, Nantes, France.
Pierre-Joseph RoyerResearch and Development, Xenothera, Nantes, France.
Gwénaëlle EvannoResearch and Development, Xenothera, Nantes, France.
Elsa LheriteauResearch and Development, Xenothera, Nantes, France.
Carine CironResearch and Development, Xenothera, Nantes, France.
Apolline SalamaNantes Université, Inserm, University Hospital Center CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.
Françoise ShneikerResearch and Development, Xenothera, Nantes, France.
Roberto DuchiTransplantation Immunology Unit, Padua University Hospital, Padova, Italy.
Andrea PerotaTransplantation Immunology Unit, Padua University Hospital, Padova, Italy.
Cesare GalliTransplantation Immunology Unit, Padua University Hospital, Padova, Italy.
Emmanuele CozziAvantea, Laboratorio di Tecnologie della Riproduzione, Cremona, Italy.
Gilles BlanchoNantes Université, Inserm, University Hospital Center CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.
Odile DuvauxResearch and Development, Xenothera, Nantes, France.
Sophie BrouardNantes Université, Inserm, University Hospital Center CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.
Jean-Paul SoulillouNantes Université, Inserm, University Hospital Center CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.
Jean-Marie BachOniris, INRAE, IECM, USC 1383, Nantes, France.
Bernard VanhoveResearch and Development, Xenothera, Nantes, France.
University of Padua · ITNantes Université · FRAvantea · ITCenter for Research in Transplantation and Translational ImmunologyInserm · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-thymocyte or anti-lymphocyte globulins (ATGs/ALGs) are immunosuppressive drugs used in induction therapies to prevent acute rejection in solid organ transplantation. Because animal-derived, ATGs/ALGs contain highly immunogenic carbohydrate xenoantigens eliciting antibodies that are associated with subclinical inflammatory events, possibly impacting long-term graft survival. Their strong and long-lasting lymphodepleting activity also increases the risk for infections. We investigated here the

Indexed as

GlobulinsOrgan TransplantationAnimalsB-LymphocytesLymphocytesRabbitsSwineTransplantation, HomologousGlobulinsanti-lymphocyte antibodyanti-lymphocyte globulininductionkidney trans plantationpig IgGpolyclonal antibodies (PAbs)solid organ transplantation

Identifiers

PMID36875084
PMCPMC9978386
OpenAlexW4321089153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.